Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action

Faruqi & Faruqi announced a federal securities class action against Regeneron covering investors who purchased shares from August 1, 2025 through May 15, 2026, with a lead-plaintiff deadline of September 14, 2026. The complaint alleges Regeneron misrepresented flaws in statistical assumptions and the clinical differentiation of its Phase III fianlimab-Libtayo study, which allegedly was unlikely to achieve statistical significance on its primary endpoint. Regeneron shares fell approximately 9.8% on May 18, 2026 following the alleged corrective disclosures.

Analysis

This is a plaintiff-lawyer solicitation rather than a new regulatory, clinical, or financial disclosure; it should not independently alter REGN’s earnings power or probability-weighted pipeline value. The investable issue is whether management’s prior characterization of the fianlimab-Libtayo program creates a broader credibility discount on oncology R&D disclosures, but that discount is unlikely to persist unless subsequent trial updates reveal a pattern of endpoint-design or internal-controls weaknesses.

Near term, incremental litigation expense should be immaterial relative to REGN’s operating cash generation and potential recoveries are typically remote and delayed. The more relevant 6-18 month impact is capital-allocation: a failed late-stage combination can reduce development spend and remove a potential source of future promotional leverage for Libtayo, while also raising the hurdle rate investors assign to earlier oncology assets. Any competitive benefit to MRK, BMY, or RHHBY is likely modest unless the failure is shown to invalidate the broader LAG-3/PD-1 combination approach rather than being trial-specific.

Contrarian view: a new lawsuit notice is not a fresh negative catalyst after the underlying clinical disappointment has been absorbed. Shorting REGN solely on legal headlines is unattractive absent evidence of a DOJ inquiry, an earnings-guidance revision, or an impairment/termination that signals materially larger lost pipeline value; the principal near-term risk to a bearish position is stabilization as investors refocus on Dupixent, Eylea HD, and the broader commercial base.

Key Decisions for Investors

• Do not initiate a new REGN short on this notice alone; treat it as non-fundamental flow. Reassess only if management cuts 2027-2028 oncology revenue expectations, discontinues additional fianlimab studies, or discloses a government investigation within the next 1-3 months.
• For existing long REGN exposure, maintain a 3-month downside hedge only if implied volatility is below the post-clinical-event range: buy a 25-delta put and finance with a 10-delta put sale. This protects against a second credibility event while avoiding an outright reduction in core-franchise exposure.
• Monitor BMY and MRK around upcoming immuno-oncology data rather than adding a broad competitive long. A long MRK/short REGN pair becomes actionable only if disclosed trial analyses attribute the result specifically to REGN’s molecule or design while Keytruda-based control outcomes remain intact; otherwise mechanism-level LAG-3 read-through could hurt BMY as well.
• Set an alert for any revision to REGN R&D guidance or formal asset impairment at the next two earnings reports. A material reduction in spending without a corresponding cut to long-term growth guidance would be constructive for REGN margins; a guidance cut would falsify the view that the event is confined to non-core pipeline optionality.